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The intestinal epithelium forms the inner layer of the human intestine and serves a wide range of diverse functions. Its constant
exposure to a vast amount of complex microbiota highlights the critical interface that this single-cell layer forms between the
host and our environment. Importantly, the well-documented contribution of environmental factors towards the functional
development of the human intestinal epithelium directly implies epigenetic mechanisms in orchestrating this complex interplay.
The development of intestinal epithelial organoid culture systems that can be generated from human tissue provides researchers
with unpresented opportunities to study functional aspects of human intestinal epithelial pathophysiology. In this brief review,
we summarise existing evidence for the role of epigenetics in regulating intestinal epithelial cell function and highlight the great
potential for human gut organoids as translational research tools to investigate these mechanisms in vitro.
1. Introduction
The intestinal epithelium serves a large variety of diverse
functions including absorption of nutrients and water as well
as forming a critical barrier to the environment [1]. The latter
requires the constant crosstalk between host cells with
luminal contents as well as a variety of immune cells located
in the underlying mucosa. Robust evidence has highlighted
the requirement of environmental factors (both host internal
and external) towards driving functional development of the
intestinal epithelium. The ability to mediate exposure to
environmental factors into potentially stable alterations of
cellular function is a hallmark of all epigenetic mechanisms
[2]. Hence, their involvement in regulating cellular function
of the intestinal epithelium during development and in
healthy homeostasis follows as a logical conclusion. More-
over, epigenetic mechanisms are increasingly being recog-
nised as the missing link between environmental triggers
and the rising incidence of several chronic noncommunic-
able diseases including those that aﬀect or originate from
the gastrointestinal (GI) tract [3]. Despite the plausible con-
cept of epigenetics as mediator of the crosstalk between
environment and cellular function, providing direct evidence
has proven to be challenging. Given the complexity of envi-
ronmental factors that might contribute to shaping the intes-
tinal epithelial epigenome in vivo, a reductionist approach
may be beneﬁcial in order to identify underlyingmechanisms.
In this respect, the development of three-dimensional orga-
noid models, which closely resemble the in vivo situation,
has provided unprecedented opportunities for scientists to
investigate fundamental aspects of cell biology. Importantly,
the ability to generate such organoids fromhuman tissues fur-
ther highlights the value of these models as translational
research tools. In this short review, we will brieﬂy summarise
current evidence supporting a key role for epigenetic mecha-
nisms with a focus on DNAmethylation in regulating cellular
function of the intestinal epithelium and highlight the value of
human gut organoid models as translational research tools to
investigate these mechanisms in vitro.
1.1. Epigenetic Mechanisms. Epigenetics can be deﬁned as any
mechanism leading to a potentially heritable change in cellu-
lar phenotype without altering the underlying DNA sequence
[2–4]. Main epigenetic mechanisms currently known to be
operative in mammals include (i) chromatin structure, (ii)
posttranslational modiﬁcations of histones, (iii) expression
of noncoding RNAs, and (iv) DNA methylation. Brieﬂy,
posttranslational modiﬁcations (PTMs) of histone tails can
alter chromatin structure and DNA accessibility, thereby
impacting on gene transcription and ultimately cellular func-
tion [5]. PTMs include phosphorylation, methylation, and
acetylation, which can lead to either silencing or activation
of associated genes [5]. In contrast, expression of noncoding
RNAs (ncRNAs) such as microRNAs (miRs) and long non-
coding RNAs (lncRNAs) regulates gene transcription by
degrading their target mRNAs or preventing their translation
[6]. A single miRNA can have multiple mRNA targets
thereby being capable of inﬂuencing complex cellular path-
ways [6]. Lastly, DNA methylation refers to the addition of
a methyl group to the cytosine in the DNA, which in mam-
mals occurs mostly in the context of a cytosine-guanine
(C-G) sequence (CpG) [7]. Although our understanding of
how DNA methylation regulates gene transcription remains
incomplete, the impact on transcription factor accessibility
and binding aﬃnity to gene promoters—either directly or
via the recruitment of methyl-CpG binding domain (MBD)
proteins—has been well documented. Furthermore, methyla-
tion may physically aﬀect the DNA by altering its mechanical
properties [8]. DNA methylation is catalyzed by a class of
enzymes named DNA methyltransferases (DNMTs), which
require a methyl donor molecule. While Dnmt1 is tradition-
ally considered the “maintenance methyltransferase” [9],
Dnmt3a and Dnmt3b, as well as Dnmtl, have been implicated
in mainly establishing “de novo”methylation marks. [10, 11].
The removal of DNA methylation marks is a complex pro-
cess and has been found to be partly regulated by
ten-eleven translocation (TET) family enzymes, member
1-3 (Tet1-3) [12–15]. Tet1 prevents hypermethylation
throughout the genome, hereby acting as a maintenance
demethylase [16, 17].
The interplay between the various epigenetic mecha-
nisms highlights the complexity of cellular regulatory net-
works and the need to develop suitable experimental
approaches to unravel their implication in health and disease.
Furthermore, the stability—or potential reversibility—of
epigenetic marks is a critical factor both with regards to the
impact on disease development as well as in light of novel
treatment approaches aimed at reversing disease associated
molecular changes.
A developmental origin of disease has been proposed for
many multifactorial, complex diseases [18]. At the heart of
this concept is the long-term exposure to certain environ-
mental factors particularly during critical, more susceptible
time periods. Considering the importance of epigenetic
mechanisms in regulating cellular development, combined
with their responsiveness to environmental factors, impli-
cates these mechanisms directly into the conceptual frame-
work of disease development.
1.2. Human Intestinal Organoid Models. Human intes-
tinal epithelial organoids (IEOs) are self-organizing,
three-dimensional structures that can be propagated long
term and diﬀerentiated into all diﬀerent epithelial cell subsets
[19, 20]. IEOs can be generated either from pluripotent stem
cells, such as embryonic or induced pluripotent stem cells
(iPSC), or by expanding adult intestinal stem cells [21].
A key expression marker of the latter is leucine-rich
repeat-containing G protein-coupled receptor 5 (Lgr5) [22];
identiﬁcation of which can be considered as a major break-
through in the development of gut organoids [19, 20, 23].
Whilst Lgr5+ adult stem cell-derived organoids give rise
to cultures that exclusively consist of intestinal epithelial
cells, pluripotent stem cell-derived organoids may also
contain mesenchymal cells [24, 25]. However, modiﬁcations
in culturing protocols also allow to generate epithelial
cell-speciﬁc intestinal organoids from iPSC [26–28].
In recent years, an increasing number of groups have suc-
cessfully established human IEO culture systems, and as a
result, the ﬁeld has seen major progress. Several studies have
provided compelling evidence that organoids closely mimic
in vivo structure and cellular dynamics. Whilst the majority
of these studies focused on small intestinal IEO, the use
of other gut regions like the colon is emerging. Impor-
tantly, it could be shown that IEOs retain distinct gut
segment-speciﬁc phenotypic diﬀerences and expression
proﬁles that closely resemble the tissue they were derived
from [29–31]. Similarly, a number of elegant studies have
shown that iPSC can be successfully diﬀerentiated to
closely mimic phenotype and gene expression of human
colonic epithelium [28, 32, 33]. More recently, work from
our group and others have started to investigate the use of
human IEOs as translational research tools to explore the
role of epigenetic mechanisms in GI development, healthy
homeostasis, and related diseases [30, 34].
2. Epigenetics in Human Intestinal Epithelial
Cell Development
The mature adult intestinal epithelium is a highly dynamic,
polarized, single-cell layer that forms the most inner lining
of the intestinal mucosa. Its diverse functions include nutri-
ent absorption, water retention, barrier function, antigen
sampling, and maintaining immune homeostasis. In order
to meet these requirements, the intestinal epithelial cell
(IEC) layer is composed of six diﬀerentiated epithelial cell
subtypes: enterocytes, goblet cells, enteroendocrine cells, tuft
cells, M-cells, and small intestinal Paneth cells [35]. All epi-
thelial cell subtypes are derived from intestinal stem cells
(ISCs), which are located in a “niche” environment at the
bottom of crypts in both the small and large intestine [35–
37]. These mostly rapidly dividing, Lgr5 expressing cells are
therefore responsible for the constant replenishment of the
epithelial cell layer, which regenerates over approximately
3-4 days [22].
As the most inner lining of the GI tract, the intestinal
epithelium is constantly exposed to a multitude of external
factors including food antigens and the diverse microbiota
[1]. From early fetal to adult life, these environmental factors
themselves undergo substantial changes and are thought to
be essential for the structural as well as functional develop-
ment of the intestinal epithelium [38–42]. During the ﬁrst
months after birth, the infant microbial composition is
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highly dynamic and under the inﬂuence of nutritional factors
such as breast- vs formula feeding and reaches a settled state
after 1-2 years [42]. On the background of an assumed stable
genome throughout the lifespan, environmentally driven
changes to phenotype imply that epigenetic mechanisms
are operative. Indeed, a number of elegant studies have
provided compelling support for this concept.
Evidence for the importance of the early postnatal time
window and speciﬁcally requirement for bacterial coloniza-
tion was provided by studies using germ-free mice. The
authors were able to demonstrate substantial diﬀerences in
intestinal epithelial DNA methylation between germ-free
and conventionally raised mice, which were found to be most
prominent during the immediate postnatal period [43, 44].
Pattern recognition receptors, such as Toll-like receptors,
are essential components of the intestinal innate immune
defence, as they are able to sense bacterial products and
mount an adequate response. As an example, studies by
Takahashi et al. provided evidence for the epigenetically
regulated expression and function of TLR4 in dependence
of bacterial colonization of the large intestine [45, 46]. In
contrast, it was shown that microbial colonization did not
aﬀect the chromatin landscape but induced strong transcrip-
tional changes [47]. Investigating these concepts in humans
is more challenging and highlights the great value of intesti-
nal organoids as will be outlined below. However, work from
our own group using primary human epithelial cell samples
has provided support for the importance of DNA methyla-
tion in regulating human intestinal epithelial cell function
in the transition from fetal to paediatric epithelium [48].
We performed simultaneous genome-wide DNA methyla-
tion and gene expression analyses on puriﬁed primary
intestinal epithelium obtained from human fetal gut and
paediatric biopsies. IEC DNA methylation was found to be
highly age- and gut segment speciﬁc with substantial
developmental methylation changes being associated with
diﬀerences in gene expression. Importantly, gene ontology
analyses of genes with dynamic DNA methylation and gene
expression changes revealed a signiﬁcant enrichment for
cellular development as well as immunological and gastroin-
testinal disease. The latter suggests that alterations in epige-
netic programming may predispose to the development of
inﬂammatory bowel diseases (IBD) [18].
The ability to derive intestinal organoids from human
fetal as well as adult gut samples combined with iPSC/ESC-
derived organoid models has opened up novel opportunities
to study human IEC development in vitro [27, 49–51]. In
recent work, our group has generated genome-wide DNA
methylation proﬁles from IEOs derived from human fetal
gut and paediatric biopsies. Comparing with epigenetic
proﬁles derived from matching primary puriﬁed epithelial
cell samples, we were able to demonstrate that organoids
retain their regional epigenetic signatures in culture [30].
Moreover, we observed striking DNA methylation changes
in fetal organoids over prolonged culture periods. Detailed
analyses revealed that these changes seemed to represent
a degree of in vitro maturation, a process, which was
partly abrogated by ablation of the demethylating enzyme
TET1 using CRISPR/Cas9 technology. In contrast, DNA
methylation signatures of organoids derived from paediatric
or adult mucosal biopsy samples were found to be much
more stable over prolonged culture periods. Together, these
ﬁndings not only provide further support for human fetal
gut organoids as highly promising tools but also conﬁrm sig-
niﬁcant changes in epigenetic plasticity between human fetal
and adult epithelium.
3. Epigenetics in Intestinal
Epithelial Homeostasis
As mentioned above, in the healthy adult intestinal epithe-
lium, rapidly cycling stem cells give rise to all epithelial cell
subsets as daughter cells which migrate up the crypt villus
axis [22]. Gene expression and cellular function of epithelial
cell subsets vary substantially, ranging from the production
of antimicrobial peptides in Paneth cells, over mucin proteins
in goblet cells to hormones secreted by enteroendocrine cells.
Hence, distinct phenotypic changes occur during the diﬀer-
entiation process on a stable genetic background, implying
the possibility of epigenetic mechanisms in contributing
towards these processes [52].
Indeed, cellular diﬀerentiation from stem cell to special-
ized cell types has been shown to involve processes of epige-
netic remodelling. Several studies performed in mice that
compared DNA methylomes of crypt versus villus epithelial
cells discovered distinct yet overall relatively minor diﬀer-
ences [53–56]. For example, Kaaij and colleagues found very
limited number of diﬀerentially methylated regions (DMRs)
between Lgr5+ stem cell and diﬀerentiated villus cells [53].
A similar study also detected DMRs with relatively small
changes of magnitude; however, these methylation changes
were found to be located at enhancers of proliferation genes
that regulate IEC cell division and diﬀerentiation [54].
Other groups have taken a diﬀerent approach by inves-
tigating the eﬀect of IEC-speciﬁc Dnmt1 ablation in mice
from birth, which was found to be associated with aber-
rant epithelial diﬀerentiation, increased apoptosis, and
DNA damage resulting in postnatal lethality [57]. Interest-
ingly, IEC-speciﬁc deletion of DNMT1 in the adult intesti-
nal epithelium led to aberrant crypt ﬁssion and expansion
with increased Lgr5 expression [54]. The retained viability
of these mice despite lack of such a critical enzyme was
thought to be compensated by upregulation of Dnmt3b.
Indeed, simultaneous deletion of both DNA methyltransfer-
ases DNMT1 and DNMT3B destroyed crypt-villus organiza-
tion and lead to reduced survival [58]. Furthermore, Dnmt1
was shown to be required for intestinal organoid establish-
ment, but not required for their maintenance [57]. Alongside
DNA methylation marks, the role of DNA hydroxymethyla-
tion (hmC) is increasingly being recognized. An in vitro
study has shown that hmC is increasing in diﬀerentiating
epithelial cells, speciﬁcally at transcription factor binding
sites of diﬀerentiation genes [59]. In a mouse model, hmC
marks were shown to be preferably gained at genes that also
increase in expression during diﬀerentiation such as
intestinal alkaline phosphatase (Alpi). Mice lacking Tet1 in
the intestinal epithelium consequently showed a reduced
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number of Lgr5+ stem cells and reduced organoid-forming
capacity [60]. This observation is comparable to the reduced
culturing capacity of human intestinal organoids with dis-
rupted TET1 [30].
In addition to DNA methylation, the role of PTH marks
in gene regulation of the intestinal epithelium has gained
increasing interest. A landmark study investigated activating
histone mark patterns (H3K27ac and H3K4me2) during the
process of diﬀerentiation of intestinal stem cells towards
enterocyte—or secretory precursors. Notably, the tested
marks remained overall similar between those cell types,
allowing for remarkable plasticity between those lineage
precursors [61]. Similarly, distribution of the silencing
H3K27me3 mark was overall unchanged between crypt and
villus compartments [62]. Chromatin accessibility, however,
was shown to change selectively to control expression of
lineage-restricted genes [63].
In light of the above, one may speculate that in the
absence of major epigenetic remodelling, the underlying
epigenetic programme of intestinal epithelial stem cells may
mediate their response to signals from the microenviron-
ment. Indeed, using human intestinal organoids derived
from diﬀerent gut segments, our group was able to show that
during an in vitro diﬀerentiation (by withdrawal of Wnt
agonists), the underlying epigenetic DNAmethylation proﬁle
determined inducibility of gut segment speciﬁc genes.
Indeed, hypomethylation induced by coculture of small
bowel organoids with DNMT inhibitors led to the induction
of colonic epithelial cell markers [30].
Together these ﬁndings illustrate how epigenetic marks
are critical for the maintenance of tissue and cell
type-speciﬁc cell function. Importantly, organoid models
have shown to provide an elegant tool to address these
fundamental questions of human intestinal cell biology.
4. Epigenetics in IEC Malfunction and Disease
Epigenetics mechanisms work at the interface between the
human genome and our environment [2]. In the context of
a changing lifestyle and environment, they thus present a
plausible framework for the rising incidence of noncommu-
nicable and complex diseases. With regards to the gastroin-
testinal (GI) tract, several cancer types have been shown to
harbour aberrant DNA methylation signatures [64–71]. For
example, in colon cancer, both a global genomic hypomethy-
lation as well as locus-speciﬁc hypermethylation have been
observed [66, 68, 72]. More speciﬁcally, a number of elegant
studies have been able to demonstrate how promoter hyper-
methylation of tumour suppressor genes can initiate tumour
growth, possibly in response to long-term exposure to spe-
ciﬁc environmental factors [72–75].
In addition to cancer, the rapid rise in the incidence of
several noncommunicable chronic inﬂammatory conditions
is increasingly being linked to environmental inﬂuences
and thereby placing epigenetic mechanisms in the spotlight
of disease pathogenesis. Amongst these conditions are
chronic inﬂammatory bowel diseases (IBD), which comprise
the two main entities, Crohn’s disease (CD) and ulcerative
colitis (UC). IBD can aﬀect patients at any age but are
increasingly being diagnosed in children and young adults
[76, 77]. Although our understanding of disease pathogenesis
remains incomplete, it is widely accepted that altered
function of the intestinal epithelium plays an important
role either in causing and/or maintaining chronic mucosal
inﬂammation in IBD patients [78]. As part of recent work,
our group performed genome-wide DNAmethylation proﬁl-
ing of puriﬁed primary intestinal epithelium obtained from
children newly diagnosed with IBD and matched healthy
controls. Results revealed disease-associated alterations in
the epigenetic proﬁle of IBD patients. Importantly, these
changes were found to be partly independent of mucosal
inﬂammation and stable over time, with altered DNA meth-
ylation levels highly correlated over the course of disease
regardless of treatment success or failure [34]. The latter sug-
gest that these epigenetic alterations may indeed contribute
towards driving chronic relapsing inﬂammation in IBD
patients. Interestingly, in contrast to these ﬁndings, full
biopsy specimens from the colon of UC patients showed
reversal of epigenetic variation upon mucosal healing [79].
The major impact of diﬀerences in cellular composition of
mixed cell tissue samples on genome-wide epigenetic proﬁles
are likely explanations for the discrepancies in these studies.
Thus, given the complexity of interactions between diﬀerent
cell types present in the intestinal mucosa as well as with their
environment (including the gut microbiota), a reductionist
approach by using IEO organoid culture model oﬀers major
advantages. These include the generation of IEO derived
from diﬀerent gut segments (e.g., aﬀected and nonaﬀected
by the disease) as well as at diﬀerent stages during the course
of disease (e.g., prior to the start and on medication). Impor-
tantly, by removing other cell types and the environmental
factors, organoid culture systems allow to speciﬁcally investi-
gate intestinal epithelial cell intrinsic mechanisms. A number
of studies have reported on the use of mucosa-derived
IEOs in the context of IBD and provided evidence for
patient-derived cultures to retain disease speciﬁc alterations
in vitro [34, 80–84]. In keeping with these reports, we were
able to demonstrate that IBD patient-derived IEOs retain at
certain loci their disease-speciﬁc DNA methylation signa-
tures in culture [34]. Together, these promising ﬁndings
strongly support the use of patient-derived IEO as trans-
lational research tools to advance our understanding of
IBD pathogenesis and to develop improved approaches to
manage these conditions.
5. Future Perspectives
Major developments in the ﬁeld of human intestinal orga-
noid culture models have highlighted their value as powerful
tools to model intestinal development and healthy homeosta-
sis as well as GI diseases. With regards to furthering our
understanding of epigenetic mechanism and how they
contribute towards the regulation of these fundamental pro-
cesses, organoid models oﬀer a number of particular advan-
tages. These include the ability to investigate cell type
intrinsic mechanisms in a purely epithelial cell-containing
model as well as the option of testing the eﬀect of indi-
vidual environmental factors on epigenetic signatures by
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performing speciﬁc coculture experiments. The latter option
will further beneﬁt from recent advances which have allowed
coculture of IEOs with other cell types such as lymphocytes
and mesenchyme [85, 86]. Last but not least, the rapid
increase in strong evidence supporting the fact that orga-
noids faithfully retain GI disease-speciﬁc features in culture
emphasises their value for the development of biobanks, drug
testing, and drug discovery in the near foreseeable future.
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